Consolidated Statements of Income (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Net revenue	$ 177,235	$ 155,753
Operating expenses:
Cost of revenue	66,867	56,714
Research and development	31,096	58,196
Selling, general and administrative	64,521	63,482
Total operating expenses	162,484	178,392
Income (loss) from operations	14,751	(22,639)
Co-promotion and profit share income	6,020	3,750
Interest expense	(3,860)	(3,674)
Other income	179	198
Income (loss) before income taxes	17,090	(22,365)
(Provision) benefit for income taxes	(22,095)	10,759
Net loss	(5,005)	(11,606)
Net loss attributable to non-controlling interest	9	33
Net loss attributable to The Medicines Company	$ (4,996)	$ (11,573)
Basic loss per common share attributable to The Medicines Company (USD per share)	$ (0.08)	$ (0.21)
Diluted loss per common share attributable to The Medicines Company (USD per share)	$ (0.08)	$ (0.21)
Weighted average number of common shares outstanding:
Basic (shares)	64,152	54,047
Diluted (shares)	64,152	54,047